椎-基底动脉延长扩张综合征的血管内治疗研究进展  

Recent advance in endovascular treatment of vertebrobasilar dolichoectasia

作　　者：葛润泽 冯欣 李西锋[1] 张炘[1] 苏世星[1] 黄驰 黄际万 段传志[1] Ge Runze;Feng Xin;Li Xifeng;Zhang Xin;Su Shixing;Huang Chi;Huang Jiwan;Duan Chuanzhi(National Clinical Key Specialty,Engineering Research Center of Cerebrovascular Disease Diagnosis and Treatment of Ministry of Education,Key Laboratory of Brain Function Repair and Regeneration of Guangdong Ordinary Colleges and Universities,Guangdong Institute of Neurosurgery,Department of Cerebrovascular Disease Surgery,Zhujiang Hospital of Southern Medical University,Guangzhou 510282,China)

机构地区：[1]南方医科大学珠江医院神经外科中心脑血管病外科,国家临床重点专科,脑血管病诊断与治疗教育部工程研究中心,广东省普通高校脑功能修复与再生重点实验室,广东神经外科研究所,广州510282

出　　处：《中华神经医学杂志》2024年第2期197-201,共5页Chinese Journal of Neuromedicine

基　　金：国家自然科学基金(82201427)。

摘　　要：椎-基底动脉延长扩张综合征(VBD)是一种罕见且具有挑战性的疾病。VBD主要与酶的作用和血流动力学的改变密切相关,以缺血性脑卒中、神经压迫症状、脑积水等临床症状为主要表现。随着VBD治疗实践以及近年来介入技术及材料的发展,VBD的血管内治疗成为焦点。本文围绕近年来VBD的血管内治疗研究进展进行综述,旨在为临床工作者提供参考。Vertebrobasilar dolichoectasia is a rare and challenging disorder.Vertebrobasilar dolichoectasia is closely related to enzyme action and hemodynamic changes,and is characterized by ischemic stroke,neurological compression symptoms,hydrocephalus,and other clinical symptoms.With development of interventional techniques and materials in recent years,endovascular treatment of vertebrobasilar dolichoectasia has become the focus.This article summarizes the current endovascular treatment of vertebrobasilar dolichoectasia,aiming to provide references for clinicians.

关 键 词：椎-基底动脉延长扩张综合征 研究进展 血管内治疗 抗血小板药物 

分 类 号：R743[医药卫生—神经病学与精神病学]